Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide

Lodé, L., Ménard, A., Flet, L., Richebourg, S., Loirat, M., Eveillard, M., … Peterlin, P. (2018, March 23). Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica. Ferrata Storti Foundation. https://doi.org/10.3324/haematol.2017.181404